Alyeska Investment Group
AMED

Alyeska Investment Group’s Amedisys AMED Stock Holding History

Alyeska Investment Group’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-282,461
Closed -$20.8M – 538
2023
Q1 		$20.8M Buy
+282,461
New +$24.4M 0.18% 156

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Alyeska Investment Group's AMED Position: Q2 2023 in Review

Alyeska Investment Group sold out of Amedisys (AMED) in Q2 2023, closing a stake of 282,461 shares — an estimated $20.8M sold.

Alyeska Investment Group first reported a position in AMED in Q1 2023 and held it in 1 quarter. The position peaked at $20.8M in Q1 2023. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

  • Alyeska Investment Group reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 282,461 Amedisys shares in Q2 2023, an estimated $20.8M.
  • Alyeska Investment Group first reported a position in Amedisys in Q1 2023 and held it in 1 quarter.
  • Alyeska Investment Group's Amedisys position peaked at $20.8M in Q1 2023.
  • 301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Alyeska Investment Group's 13F filing for Q2 2023, filed 14 Aug 2023.